The purchase price for the assets is $11 million subject to adjustment for changes in working capital to be determined subsequent to the closing date.
Eamonn Hobbs, president and CEO of AngioDynamics, said: “With the acquisition of Diomed’s assets, AngioDynamics has substantially strengthened its position in the worldwide market for the treatment of varicose veins.”